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Background: Lung allografts contain large amounts of iron (Fe), which inside lung macrophages may promote
oxidative lysosomal membrane permeabilization (LMP), cell death and inflammation. The macrolide antibiotic
azithromycin (AZM) accumulates 1000-fold inside the acidic lysosomes and may interfere with the lysosomal pool
of Fe.
Objective: Oxidative lysosomal leakage was assessed in lung macrophages from lung transplant recipients without
or with AZM treatment and from healthy subjects. The efficiency of AZM to protect lysosomes and cells against
oxidants was further assessed employing murine J774 macrophages.
Methods: Macrophages harvested from 8 transplant recipients (5 without and 3 with ongoing AZM treatment) and
7 healthy subjects, and J774 cells pre-treated with AZM, a high-molecular-weight derivative of the Fe chelator
desferrioxamine or ammonium chloride were oxidatively stressed. LMP, cell death, Fe, reduced glutathione (GSH)
and H-ferritin were assessed.
Results: Oxidant challenged macrophages from transplants recipients without AZM exhibited significantly more
LMP and cell death than macrophages from healthy subjects. Those macrophages contained significantly more Fe,
while GSH and H-ferritin did not differ significantly. Although macrophages from transplant recipients treated with
AZM contained both significantly more Fe and less GSH, which would sensitize cells to oxidants, these
macrophages resisted oxidant challenge well. The preventive effect of AZM on oxidative LMP and J774 cell death
was 60 to 300 times greater than the other drugs tested.
Conclusions: AZM makes lung transplant macrophages and their lysososomes more resistant to oxidant challenge.
Possibly, prevention of obliterative bronchiolitis in lung transplants by AZM is partly due to this action.
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Lung macrophages function as large recipients of iron
(Fe) [1-5]. By depositing ferruginous material inside their
lysosomes potentially hazardous Fe becomes separated
from reactive oxygen species (ROS) by intracellular anti-
oxidative enzyme systems [1-5]. Following the enzymatic
digestion of degradable Fe-containing material (executed
by lysosomal enzymes working at acidic pH), liberated
Fe becomes re-utilized in different cellular processes that* Correspondence: Lennart.Persson@lio.se
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distribution, and reproduction in any mediumrequire this metal [6,7]. However, lysosomes are acidic
(pH 4.5-5.5) and rich in reducing equivalents (e.g., cyst-
eine); thus, free or loosely bound lysosomal Fe will partly
exist in a redox-active ferrous state (Fe2+) [8,9]. If hydro-
gen peroxide (H2O2) escapes the protective shield of
antioxidants, aggressive hydroxyl radicals (HO•) or simi-
larly reactive Fe-centered radicals may be generated in-
side lysosomes by Fenton-type chemistry (Fe2+ +
H2O2! Fe3+ + HO- +HO•) [3-6,10-12]. The ensuing
oxidative damage on the lysosomal membranes, which
leads to lysosomal membrane permeabilization (LMP)
and the leakage of lysosomal Fe and hydrolytic enzymes
in to the cytosol, may result in cell death [3-6,10-12].
The cytosolic enzymes caspase-3 and −9, which areCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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come activated [13,14]. If the cell death is extensive, the
lung macrophages often fail to phagocytose all of the
apoptotic cells, and the resulting post-apoptotic necrosis
may promote inflammation and fibrosis [10-12,15-19].
The bronchiolitis obliterans syndrome (BOS) is a
fibro-proliferative disease of poorly understood etiology
that is characterized by an irreversible decline in allo-
graft function due to fibrotic remodeling of small air-
ways, i.e. obliterative bronchiolitis (OB) [20]. The
macrolide antibiotic azithromycin (AZM) is a promising
drug for the prevention of (BOS) [21]. Recently, a rando-
mized, double-blind, placebo-controlled study provided
evidence that lung allograft recipients, who received a
low-dose of AZM (250 mg three times per week) con-
tinuously from the time of the post-transplantation hos-
pital discharge, demonstrate a significantly lower
incidence of BOS over a 2-yr follow-up period (12.5%
compared to 44.2% in those who received placebo) [21].
Previous observations on chronic inflammatory lung dis-
ease support the idea that the protective effect of AZM
on the airways is anti-inflammatory/immunomodulatory
rather than antimicrobial [22,23]. AZM enters cells and
lysosomes by nonionic diffusion [24-26]. The molecule
is amphiphilic bearing two basic functions with appro-
priately weak pKa values [8.1 for the endocyclic tertiary
amine and 8.8 for the tertiary amine carried by one of
the two sugar moieties (desosamine)] [24-26]. Thus,
AZM is a weak base and lysosomotropic, i.e., AZM is
protonated, trapped and concentrated up to > 1000-fold
inside the acidic lysosomes [24-26].
Previously, we have shown that weak bases may at-
tenuate the reactivity of lysosomal Fe, which protects
lysosomes and cells against oxidative challenge [27-29].
This effect is achieved by the drug either (i) similar to
the radio-protective agent amifostine and the synthe-
sized derivative of the antioxidant α-lipoamide, α-lipoic
acid-PLUS, which work as Fe-chelators [27,28] by stably
binding intra-lysosomal Fe, or (ii) by raising the pH in
the acidic vacuome, which blocks the uptake of Fe from
the transferrin/transferrin-receptor complex in late
endosomes and/or inhibits the enzymatic liberation of
Fe from Fe-rich organic elements such as ferritin and
worn-out mitochondria inside lysosomes [29].
Building on this previous research, we tested and
found for the first time that the lung macrophages (and
their lysosomes) from lung transplant recipients without
AZM treatment are more susceptible to an oxidant chal-
lenge than the lung macrophages that originate from
healthy subjects. In contrast, oxidant-exposed macro-
phages from transplant recipients treated with AZM did
not exhibit lysosomal damage and dead cells were few.
Results from oxidant-challenged murine macrophage-
like J774 cells indicate that the cytoprotective potency ofAZM on a molar basis is much greater than that of a
high-molecular-weight derivative of the Fe chelator des-
ferrioxamine (H-DFO) or ammonium chloride (NH4Cl).
Methods
Ethical considerations
The study protocol was approved by the local Ethical
Committee (Linköping, Sweden) according to the guide-
lines of the Helsinki Declaration.
Study population
Following informed consent, bronchoscopies with
bronchoalveolar lavage (BAL) were carried out. The
control group was 7 healthy, non-smoking subjects [in
all cases pulmonary disease was thoroughly ruled out by
a chest X-ray, lung function test and bronchoscopy].
The lung transplant recipients were 5 patients without
AZM treatment who underwent surveillance post-
transplantation BAL with transbronchial lung biopsies
at 3 and 6 months and 3 patients with AZM treatment
(250 mg three times per week) who were investigated to
rule out rejection and/or infection. Transplant recipients
with AZM were transplanted 11, 6 and 2 yrs before
bronchoscopy and were treated with AZM for 42, 1 and
2 months, respectively. All transplant recipients received
conventional triple-drug immunosuppression [with
methylprednisolone, a calcineurin inhibitor (cyclosporine
A or tacrolimus) and a cytostatic agent (mycophenolate
mofetil)], conventional infectious prophylaxis [for cyto-
megalovirus, Aspergillus spp. and Pneumocystis spp.]
and conventional prophylaxis for gastro-esophageal re-
flux (with the proton pump inhibitor omeprazol). None
of the transplant recipients were diagnosed with infec-
tion and/or rejection when the bronchoscopy was per-
formed. The demographic details of the subjects and the
BALF characteristics are presented in Table 1.
Cell cultures and treatments
Briefly, BAL was performed by a standardized washing
of the middle lobe or lingula of the lung (transplant) for
6–9 times with 20 mL of sterile 0.9% (w/v) saline solu-
tion during a fibreoptic bronchoscopy [12]. None of the
BAL fluid (BALF) was stained with blood. The BALF
samples were centrifuged at 200xg for 10 min. Leuco-
cytes from the BALF were counted and seeded in
35 mm Petri dishes (± cover slips) and the lung macro-
phages were allowed to attach. Concomitantly, murine
J774 macrophages were seeded at the same density.
After a thorough rinse in phosphate-buffered saline
(PBS), the dishes, which contained approximately 0.4 x
106 attached lung macrophages or J774 cells/dish, were
returned to standard culture conditions. Both cell types
were cultured in Dulbecco’s Modified Eagle’s Medium
supplemented with 100 IU/ml penicillin, 100 μg/ml
Table 1 Patient and BALF characteristics of the population studied
Lung transplant recipients
without AZM (n= 5)
Lung transplant recipients
with AZM (n= 3)
Healthy control patients
(n = 7)
Mean age 48 ± 18 44 ± 13 60 ± 13
Gender 4 females/1 male 2 females/1 male 2 females/5 males
BAL recovery (ml) 122± 20 100 ± 8 110 ± 18
Cell count
(106 cells/L) 308± 139 268 ± 84 244 ± 184
% macrophages 84 ± 14 80 ± 9 92 ± 5
% lymphocytes 13 ± 10 6 ± 4 4 ± 3
% neutrophils 3± 6 14± 10 4 ± 4
% eosinophils 0± 0 0 ± 0 0 ± 1
% basophils 0± 0 0 ± 0 0 ± 0
Data are presented as the means ± 1 SD. BAL bronchoalveolar lavage.
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GIBCO, Paisley, UK) and 10% fetal bovine serum (PAA
Laboratories GmbH, Pasching, Austria) under standard
culture conditions for 48 h. Before the experiments, all
dishes were thoroughly rinsed in PBS. J774 macrophages
were pre-treated (or not) as described below and then
rinsed again. Both cell types were oxidatively stressed by
glucose oxidase (GO; Sigma-Aldrich Inc., St. Louis, MO,
USA). GO was added directly to the culture medium for
60 min under standard culture conditions. Under these
conditions, a stable concentration of approximately
120 μM H2O2 was generated in the culture medium.
By employing J774 macrophages, the protection
afforded by AZM on oxidant-challenged lysosomes and
cells were further explored. For this purpose we used
two reference compounds, both well known to attenuate
the reactivity of lysosomal Fe. Thus, the pre-treatments
were with AZM at 33–660 μM for 45 min to 4 hrs, H-
DFO (which is a strong Fe chelator that exclusively tar-
gets the lysosomal compartment) at 2 mM for 4 hrs
[30], or NH4Cl at 10 mM for 4 hrs, which blocked the
enzymatic liberation of Fe in lysosomes by raising the
pH to reduce the amount of available lysosomal Fe [29].
Ampoules of AZM (Pfizer Inc., Sweden) for intravenous
use were reconstituted with distilled water to 100 mg/
mL and diluted to the required concentrations with dis-
tilled water. The appropriate concentrations and expos-
ure time that were utilized for NH4Cl and H-DFO were
based on previous studies on J774 macrophages, which
demonstrated optimal reduction of lysosomal Fe reactiv-
ity and maintained viability [29,30].
To confirm the lysosomotropism of AZM, J774
macrophages were pretreated with 10 mM NH4Cl for
5 min (which raised the lysosomal pH and largely pre-
vented the lysosomal uptake of AZM) and then exposed
to AZM in the continued presence of NH4Cl. Following
its dissociation to NH3, H
+ and Cl-, NH3 (pKa = 9.2)
becomes protonated and trapped in the lysosome asNH4
+, which substantially increases the intralysosomal
pH [31] and prevents the accumulation of lysosomotro-
pic substances with lower pKa values, such as AZM [27].
Prussian blue staining of ferric Fe
The cells grown on cover slips were fixed in paraformal-
dehyde and stained for ferric Fe (Fe3+) by the Prussian
blue staining procedure [11]. The cellular content of
Fe3+ was scored independently by two examiners accord-
ing to the method reported by Golde et al. [32]. Thus,
200 lung macrophages/cover slip were counted, and each
macrophage was graded on a scale of 0–4; 0 = no blue
color, 1 = faint blue staining in cytoplasm, 2 = dense blue
color in minor portion of cytoplasm or medium color in-
tensity throughout cell, 3 = deep blue staining in most of
cytoplasm, 4 = dark blue throughout cytoplasm. A mean
score, i.e. the Golde Index, for 100 macrophages was then
calculated; zero being the minimum and 400 the max-
imum score.
Determination of total cellular Fe, H-ferritin and reduced
glutathione
The total cellular Fe was estimated using atomic absorp-
tion spectrophotometry, equipped with an iron lamp
(243.3 nm), with a lower detection limit of 0.65 μg Fe/L
[11]. The cellular expression of the ferritin heavy (H-fer-
ritin) chain in cell lysates was determined by an ELISA
analysis (MyBioSource, CA, USA) according to the man-
ufacturer’s instructions. Reduced glutathione (GSH) was
estimated by the Glutathione Assay Kit (BioCat GmbH,
Heidelberg, Germany) using a Wallace 1420 Victor Plate
Reader (PerkinElmer, Waltham, MA, USA). The Fe, H-
ferritin and GSH contents were normalized to the pro-
tein concentration of each sample [11].
Assessment of lysosomal membrane permeabilization
Acridine orange (AO; Gurr, Poole, Dorset, UK), which is
a metachromatic fluorophore and lysosomotropic weak
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inside acidic lysosomes. Using flow cytometry, the
lysosomal leakage of AO (and protons) in to the
cytosol of lung macrophages and J774 cells was assessed
by determination of the mean value of AO-green fluores-
cence (the AO-relocation test) [27]. Upon blue light exci-
tation, the AO that is bound to proteins and DNA in the
cytosol and nuclei emits a weak green fluorescence, which
increases when the lysosomes leak AO. Alternatively, the
AO is highly concentrated in lysosomes and emits an in-
tense red fluorescence upon excitation. The AO-
relocation test is sensitive and able to monitor early and
minor LMP. The method was thoroughly standardized for
lung macrophages using identical settings and J774
macrophages, equally exposed to oxidants in parallel
experiments, were used as a reference. Briefly, the cells
were rinsed in PBS, stained with AO (2.5 μg/mL) for
15 min at 37°C, rinsed 3 times with complete culture
medium, oxidatively stressed in the presence of GO and
rinsed with culture medium before the analysis was per-
formed immediately after the 1-h oxidant exposure. To
initiate controlled LMP the synthetic lysosomotropic de-
tergent O-methyl-serine dodecylamide hydrochloride
(MSDH; kindly provided by Gene M. Dubowchik, Bristol-
Myers Squibb, Wallingford, CT, USA) was used. The
green (FL1= 530 nm) fluorescence was recorded on log
scale using a BD LSR Flow Cytometer (Becton-Dickinson,
Mountain View, CA, USA) that was equipped with a 488-
nm exciting argon laser. CellQuest software was used for
data acquisition and analyses. Data are expressed as arbi-
trary units (A.U.).
Micrographs of J774 macrophages exposed to MSDH
were also taken. Briefly, cells seeded on cover-slips were
incubated with AO (2.5 μg/mL) for 15 min at 37°C,
washed with PBS, and placed on the stand of a LMS
Zeiss laser scanning confocal microscope. AO was
excited using a 488 nm light from a 100-mW diode laser,
and leakage of AO (and concomitant loss of the lyso-
somal proton gradient) during the MSDH exposure was
followed by laser scanning micrographs in a channel
defined by band-pass filters for 495–555 nm and
630 nm.
Cell death assays
The frequency of cells with an apoptotic or necrotic
morphology (i.e., cytoplasmic budding/pycnotic frag-
mented nuclei/apoptotic bodies and membranous rup-
ture/nuclear swelling, respectively) was estimated by
phase contrast microscopy in a blinded fashion. 0.5 ×
103 cells/dish were counted in preselected fields. Ten
hrs after ended oxidative stress, the fractions of cells
(apoptotic or necrotic)/initial numbers of cells within
the fields were determined. Detached cells were all nec-
rotic. At the same time point the fraction of fragmentedapoptotic DNA was assessed using hypotonic propidium
iodide (Sigma Chemical Co., St. Louis, MO, USA) and
cytofluorimetric analysis [11]. According to the manu-
facturer’s instructions, the fluorescence of AMC (7-
amino-4-methyl-coumarin), which was liberated from
Ac-DEVD-AMC (Becton-Dickinson, Mountain View,
CA, USA) by active caspase-3-like caspases, was also
analyzed in lung macrophages using a Wallace 1420 Vic-
tor Plate Reader (PerkinElmer, Waltham, MA, USA)
during the 1-h oxidant challenge and up to 5 h after the
end of the oxidative stress. The increase of caspase-3 as
a percent of the control was determined, and the peak
value was recorded.
Statistical analysis
The results were reported as the means ± 1 SD. Statis-
tical comparisons were made using an ANOVA followed
by a Tukey’s post-hoc test for p < 0.05 (*), p < 0.01 (**)
and p < 0.001 (***).
Results
Lung transplant macrophages are more susceptible to
oxidants if not treated with AZM
The baseline green AO fluorescence values of lung
macrophages from lung transplant recipients without
AZM were significantly higher than those of the lung
macrophages from healthy subjects. This observation
might indicate that lysosomes in the lung transplant
macrophages were more prone to leakage from the start
and/or that the content of AO-binding proteins and
DNA was higher than in the macrophages from healthy
subjects (Figure 1A). However, following oxidative stress,
macrophages from transplant recipients without AZM
exhibited significantly higher green AO fluorescence
values that corresponded to more lysosomal leakage of
AO compared to the macrophages from healthy subjects
(Figure 1A). Indeed, upon an oxidant challenge, the in-
crease of green fluorescence was 44 ± 18 A.U. in the
transplant macrophages, but only 19 ± 16 A.U. in the
lung macrophages from healthy subjects (p < 0.05). In
contrast, the macrophages from lung transplant recipi-
ents with AZM displayed a slight decrease of AO green
fluorescence (−6 ± 6) upon oxidant challenge, which was
significantly less than the increase of AO green fluores-
cence observed in the macrophages from the healthy
subjects (p < 0.01) (Figure 1A).
Compared to cultures of lung macrophages from the
healthy subjects, cultures of macrophages from trans-
plant recipients without AZM displayed significantly
more dead cells, including both apoptotic (p < 0.01) and
necrotic cells (p < 0.05) (Figure 1B). In cultures of
macrophages from transplant recipients with AZM
apoptosis and necrosis were significantly less than in




































































Figure 1 (A) Lysosomal membrane permeabilization (LMP) and
(B) cell death (apoptosis, necrosis and total cell death) in
cultures of oxidatively stressed human lung macrophages that
were retrieved from healthy subjects (n = 7), lung transplant
recipients without azithromycin (n = 5) and with azithromycin
treatment (AZM; 250 mg three times per week) (n = 3). LMP was
assessed by cytosolic/nuclear green fluorescence due to acridine
orange leakage into the cytosol (arbitrary units; A.U.) in non-
oxidatively stressed lung macrophages (open symbols) and
oxidatively stressed lung macrophages immediately after a 1-h
oxidant exposure (filled symbols). Cell death, which appeared 10 h
after the end of oxidant challenge, was assessed by typical
morphology using a phase contrast microscope and by the fraction
of apoptotic DNA (both methods gave similar results for apoptosis).
In the non-oxidatively stressed cultures, cell death was < 3%. For
details, see the Methods section. Values are the means ± 1 SD.
Significant differences are indicated as follows: * p < 0.05 and
** p< 0.01, # p < 0.05 and ## p < 0.01 (vs. healthy subjects), } p< 0.05
and }} p< 0.01 (vs. transplant recipients without AZM).
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(Figure 1B).
Apoptosis is often associated with increased activity of
caspase-3. Correspondingly, oxidant-challenged macro-
phages from transplant recipients without AZM
expressed high peak values of caspase-3 activation (321;
% of controls). However, apoptosis may also occur with-
out caspase-3 activation [33]. This possibility and signifi-
cant necrosis might explain the great variation found (1
SD=571%). Consequently, the caspase-3 activationobserved in oxidatively stressed macrophages from reci-
pients without AZM this did not statistically differ from
the caspase-3 activation observed in macrophages from
healthy control subjects (45 ± 54; mean value ± 1 SD;% of
controls). This analysis was not performed on macro-
phages from transplant recipients with AZM because of
limited sample size.Iron is increased in lung transplant macrophages
Cell features that are decisive for lysosomal Fe reactivity
were evaluated in the lung macrophages and the results
are summarized in Table 2. The mean value for the
Golde index, which is based on a cytochemical staining
of ferric Fe, of macrophages that were retrieved from
transplants recipients without and with AZM were sig-
nificantly increased compared to that of the healthy con-
trol subjects (55.8 ± 37.2 (p < 0.05), 71.7 ± 15.1 (p < 0.05)
and 8.2 ± 11.9, respectively). The Golde index normally
ranges from 4 to 25 [34]. Figure 2 illustrates representa-
tive lung macrophages from healthy subjects and lung
transplant recipients. Total cellular Fe assessed by
atomic absorption demonstrated significantly more Fe in
macrophages from transplant recipients without AZM
(p < 0.05) and with AZM (p < 0.05) than in macro-
phages from healthy subjects. Indeed, there was even
significantly more Fe in macrophages from transplant
recipients with AZM than in macrophages from trans-
plant recipients without AZM (p < 0.05). The cellular
levels of the major antioxidant GSH in the macrophages
from transplant recipients without AZM and healthy
subjects were similar, while GSH was significantly
decreased in macrophages from transplant recipients
with AZM (p < 0.05; compared to the macrophages from
healthy subjects). Compared to healthy subjects, the
level of the cytoprotective H-ferritin in the macrophages
from transplant recipients without AZM was slightly but
not significantly increased. This assay was not performed
on macrophages from transplant recipients with AZM
due to limited sample size.Azithromycin efficiently protects J774 macrophages and
lysosomes against oxidants
A 4-h exposure to a range of AZM concentrations (33–
660 μM) effectively protected lysosomes in J774 macro-
phages against an oxidant challenge (data not presented).
As opposed to 4-h exposures to millimolar concentra-
tions of H-DFO or NH4Cl, even a short exposure time
(45 min) to a low concentration (33 μM) of AZM proved
to be equally efficient (Figure 3A). Importantly, oxidant-
induced LMP was prevented by micromolar concentra-
tions of AZM, while millimolar doses of H-DFO or
NH4Cl for 4 h were needed to achieve full protection of
the lysosomes against oxidant injury (Figure 3A).
Table 2 Cell features that are decisive for lysosomal Fe2+-reactivity in human lung macrophages
ASSAYS Lung transplant recipients
without AZM (n= 5)
Lung transplant recipients
with AZM (n= 3)
Healthy control patients
(n = 7)
Golde Index 55.8 ± 37.2 (0.024) 71.7 ± 15.1 (0.013) 8.2 ± 11.9
Cellular iron (ng/mg protein) 11.2 ± 7.8 (0.048) 29.6 ± 23.6 (0.028) 4.5 ± 2.5
H-ferritin (ng/mg protein) 94.2 ± 76.3 (0.136) *Not done 29.8 ± 19.8
GSH (ng/mg protein) 40.8 ± 20.1 (0.890) 28.3 ± 3.9 (0.012) 39.9 ± 8.1
Data are presented as the means ± 1 SD. P-value vs. healthy control patients is indicated. *The assay was not performed because of the size of the sample.
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ure to 50 and 100 μM of the lysosomotropic detergent
MSDH resulted in a significant increase of AO-green
fluorescence (p < 0.05 and p < 0.05, respectively), which
was dose-dependent (p < 0.05) (Figure 3A). Figure 3B
and 3C are detailed micrographs of J774 macrophages
before (Figure 3B) and after exposure to 200 μM MSDH
(Figure 3C). Within a few minutes MSDH caused exten-
sive lysosomal disruption resulting in a massive leakage
of AO into the cytosol (Figure 3C).
We also observed that AZM, H-DFO and NH4Cl
caused an effective prevention of oxidant-induced cell
death (Figure 4). To test whether or not the protection
of J774 macrophages by AZM was due to the accumula-
tion of this drug inside the lysosomes in a pH-
dependent way, cultures were pretreated with NH4Cl
before being exposed to AZM in the continued presence
of NH4Cl. The normal pH inside the macrophage lyso-
somes is about 4.5, but upon addition of 10 mM NH4Cl,
the lysosomal pH increases almost instantly. Under such
circumstances, the cytoprotective effect by AZM was
abolished (Figure 4).
Finally, we employed J774 macrophages to test
whether or not AZM, H-DFO or NH4Cl had an influ-
ence on the cell features that are important for lyso-
somal Fe-reactivity, which are mainly Fe and the GSH
and H-ferritin contents of the cells. However, such an
interference of significance was thoroughly ruled out,
and the results are summarized in Table 3.A B
Figure 2 Prussian blue-stained Fe in lung macrophages that were har
recipient (without azithromycin). Note the greater amount of Fe in the l
heterogeneity in the distribution of Fe.Discussion
To the best of our knowledge, the present study is the
first to demonstrate that the lysosomes of lung macro-
phages from lung transplant recipients are more suscep-
tible to oxidative stress than the lysosomes of lung
macrophages originating from healthy humans. Oxidant
challenge led to a concomitant and pronounced lung
allograft macrophage deaths (Figure 1). In contrast,
macrophages from transplant recipients with AZM sur-
vived oxidant challenge significantly better and their
lysosomes were efficiently protected against oxidants
(Figure 1). This was despite the fact that macrophages
from transplant recipients with AZM contained signifi-
cantly more Fe and less GSH (Table 2), which both favor
a pro-oxidative state of these macrophages. This obser-
vation does, indeed, indicate a significant protection
afforded by AZM on oxidatively stressed lysosomes and
cells. The differences noticed regarding Fe and GSH be-
tween the two groups of lung transplant macrophages is
probably explained by macrophages with AZM being
retrieved from much older transplants. Rejection and in-
fection, other reasonable causes behind a sensitization
towards oxidants, were not detected in any of the two
groups.
Lung macrophages may provide an efficient defense
against Fe-catalyzed oxidative lung tissue damage by
harboring potentially harmful Fe inside their lysosomes
[1-5]. Lung macrophages digest both organic Fe-
containing elements, such as hemoglobin derived fromvested from (A) a healthy subject and (B) a lung transplant












































Figure 3 (A) Lysosomal membrane permeabilization (LMP) in cultures of murine J774 macrophages that were treated with
azithromycin (AZM) for 45 min or high-molecular-weight desferrioxamine (H-DFO)/ammonium chloride (NH4Cl) for 4 h at the indicated
concentrations and then oxidatively stressed. To initiate controlled LMP the lysosomotropic detergent MSDH was used. LMP was assessed by
the cytosolic/nuclear green fluorescence due to the acridine orange leakage into the cytosol (arbitrary units; A.U.) in non-oxidatively stressed/
non-MSDH treated cells (open symbols) and in oxidatively stressed/MSDH treated cells immediately after a 1-h oxidant exposure (filled symbols).
NH4Cl-treated J774 macrophages exhibited pronounced granularity (observed by phase contrast microscopy) that resulted in a reduced emission
of green fluorescence. Values are the means ± 1 SD (n= 6; independently performed). Significant differences are indicated as # p < 0.05 (cells
either oxidatively stressed or MSDH treated vs. non-oxidatively stressed/non-MSDH treated control cells). * p < 0.05. (B) Detailed micrograph of
control cells stained with AO. Lysosomes loaded with AO appear as red-fluorescent dots, while AO at a low concentration (e.g. AO-binding
nuclear structures) emits a weak green fluorescence. (C) Detailed micrograph of the same cells following treatment with 200 μM MSDH for 5 min.
Note cell shrinkage, an almost complete loss of intact red-fluorescent lysosomes and a massive leakage of AO into the cytosol, the latter resulting
in a strong green fluorescence emitted from the nucleus and the surrounding cytoplasm.
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e.g., silica [10-12]. Thus, in studies of lung macrophages
that were harvested from a patient with ongoing pul-
monary bleeding, we observed a dramatic increase of H-
ferritin, which efficiently protected lysosomes and cells
that were excessively loaded with Fe against oxidative in-
jury [12]. H-ferritin is known to rapidly and copiously
sequester reactive Fe [35], thereby acting as a custodian
against Fenton-type chemistry outside as well as inside
the lysosomes [4-6,10-13]. The latter is possible because
the ferritin molecule normally is never completely Fe-saturated and therefore temporarily binds the lysosomal
Fe in an un-reactive state before being degraded [4-
6,12,13]. GSH contributes to the protection by scaven-
ging free radicals in the cytosol and by working as an
electron donor for glutathione peroxidases through
which H2O2 is reduced to water [4,5,10-13].
However, this defense system by the lung macrophages
might be over-whelmed if the cells and lysosomes are
exposed to excessive Fe [10,11]. In a case of pulmonary
alveolar proteinosis, we have previously shown that






































Figure 4 Cell death in cultures of murine J774 macrophages
that were treated with azithromycin (AZM) for 45 min or high-
molecular-weight desferrioxamine (H-DFO)/ammonium chloride
(NH4Cl) for 4 h at the indicated concentrations and then
oxidatively stressed. Cell death, which appeared 10 h after the end
of the oxidant challenge, was assessed by typical morphology using
a phase contrast microscope and by the fraction of apoptotic DNA
(both methods gave similar results for apoptosis). In some
experiments, the cells were pretreated with 10 mM NH4Cl for 5 min
(to raise the lysosomal pH, which largely prevented the uptake of
the lysosomotropic compound AZM) and then exposed to AZM in
the continued presence of NH4Cl (for details see the Methods
section). In the non-oxidatively stressed cultures, cell death was < 3%.
Values are the means ± 1 SD (n = 4; independently performed).
Significant differences are indicated as follows: ** p < 0.01 and
*** p < 0.001 (vs. controls) and } p< 0.05 (AZM+NH4Cl treated cells
vs. AZM treated cells).
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that resulted in pronounced lung macrophage death
[11]. This scenario might also explain the response to
oxidant challenge observed in the present study in cul-
tures of macrophages from lung transplant recipients
without AZM (Figure 1). In vivo, extensive necrotic
death of oxidant-exposed lung macrophages results in
the release not only of harmful hydrolytic enzymes to
the epithelial lining fluid (ELF) from the interior ofTable 3 The influence of different 4-hr treatments (for details
for lysosomal Fe2+-reactivity in murine 774 macrophages
ASSAYS Cont. AZM (
33
Golde Index (n= 3) 0.7 ± 0.8 0.6 ± 0.7
Cellular iron (ng/mg protein) (n = 4) 0.2 ± 0.1 0.2 ± 0.0
H-ferritin (ng/mg protein) (n = 3) 6.9 ± 1.4 8.2 ± 2.4
GSH (ng/mg protein) (n = 4) 21.3 ± 2.0 20.7 ± 1.6
To evaluate the different assays, the analysis was also performed on J774 macropha
means ± 1 SD. *, ** and *** indicate a significant difference from untreated controldisrupted lysosomes [36] but also of reactive Fe from the
same organelle [2-5]. This is probably a major reason be-
hind the increased amounts of reactive ELF-Fe, which
subjects the respiratory epithelium to increased oxidative
stress [4,5], that is also observed in many inflammatory
lung diseases [2,3].
Analyses of the possible reasons behind the observed
susceptibility of lysosomes and cells to an oxidant chal-
lenge reveal that the anti-oxidant status of macrophages
from transplant recipients without AZM is changed to-
ward a pro-oxidative state. This is probably the result of
significantly increased amounts of Fe, which are not suf-
ficiently compensated for by an increase of H-ferritin
(Table 2). The amounts of GSH were similar in the
macrophages from both the transplant recipient without
AZM and the healthy subjects (Table 2). Although we
emphasize the increased lysosomal Fe reactivity as the
most likely reason for a significantly increased suscepti-
bility of lysosomes in lung transplant macrophages with-
out AZM to oxidative stress, we also notice a significant
gender mismatch in the present study (Table 1). A gen-
der dependency for the lysosomal susceptibility to oxida-
tive stress seems unlikely but cannot be ruled out by our
current research on lung macrophages.
All lung transplant recipients, without AZM or with
AZM, were on prophylaxis treatment with omeprazol
against gastro-esophageal reflux. Since this drug is a pro-
ton pump inhibitor, theoretically, it has the potential to
inhibit AZM-mediated cytoprotection by blocking the
lysosomal uptake and accumulation of AZM through
alkalinizing the lysosomes [37,38]. However, lysosomes
of macrophages from transplant recipients with AZM
were efficiently stabilized in contrast to the lysosomes of
the macrophages without AZM. This finding strongly
speaks against this theory and is, in fact, well in line with
previous studies of different cell types demonstrating no
effect of omeprazol on lysosomes regarding their integ-
rity [39,40], activity of lysosomal enzymes [39,40] or
their acidification [41].
AZM is known to cause an accumulation of phospho-
lipids and cholesterols inside lysosomes, which is an ef-
fect mediated by the interaction with phospholipids andsee Methods section) on cell features that are decisive
μM) H-DFO (mM) NH4Cl (mM) FeCl3 (μM)
660 2 10 100
0.5 ± 0.5 0.2 ± 0.4 0.4 ± 0.6 194.3 ± 6.1***
0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 16.2 ± 2.3***
8.6 ± 1.7 7.6 ± 1.9 6.0 ± 1.8 109.8 ± 9.7**
23.2 ± 3.3 20.2 ± 2.0 26.3 ± 3.9 26.3 ± 3.8*
ges that were exposed to 100 μM FeCl3 for 16 h. Data are presented as the
cells of p < 0.05, p < 0.01 and p< 0.001, respectively.
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accumulation (i.e., lysosomal phospholipidosis) has pre-
viously been proven to greatly increase the lysosomal re-
sistance to oxidative stress [44,45]. All transplant
recipients with AZM were on this treatment since at
least a month before lung macrophages were harvested
and studied. Clearly, this long-term effect by AZM on
lysosomes of macrophages from transplant recipients
treated with the same drug cannot be ruled out as a sig-
nificant mechanism behind the protection observed in
the present study.
Similar to NH4Cl, AZM may also decrease the lyso-
somal pool of Fe by raising the pH inside the acidic
vacuome (late endosomes and lysosomes), thus blocking
the uptake of Fe from the transferrin-transferrin-
receptor complex occurring in the late endosomes [46]
and/or preventing the enzymatic liberation of Fe from
Fe-containing organic material accumulating inside the
lysosomes [24,26,29,47]. However, assessment of
Prussian-blue stained Fe in the macrophages (i.e., the
Golde index) from transplant recipients with AZM did
not indicate that this scenario occurs in vivo. In contrast,
the Golde index of macrophages from recipients with
AZM tended to be higher, not less, than that of macro-
phages from recipients without AZM. Moreover, protec-
tion of J774 macrophages against oxidative stress was
afforded by only a 45-min AZM exposure. It takes many
hrs of lysosomal alkalinization to achieve this effect on
the lysosomal pool of Fe and its reactivity [29,47]. More-
over, a short exposure to AZM (4 hrs) had no significant
effect on the cellular content of Fe, GSH and H-ferritin
in J774 macrophages. Collectively, these findings do, in-
deed, suggest a more immediate mode of action by
AZM on lysosomes. Importantly, test tube experiments
indicate that AZM forms a relatively stable 1:1 complex
with Fe2+ [48]. The lactone ring in the AZM molecule is
substituted with a number of hydroxyl and amine func-
tional groups that are positioned in a suitable configur-
ation for interaction with Fe.
H-DFO is a potent chelator of Fe, which exclusively
targets the lysosomal pool of Fe [30]. This is because H-
DFO is a high-molecular-weight neutral polymer that
cannot be degraded by the lysosomal enzymes, and,
thus, remains permanently inside the lysosomal com-
partment after endocytic uptake [30]. AZM and H-DFO
prevented LMP and cell death to a similar extent (Figure 3
and Figure 4). On a molar basis, AZM was 60 times more
efficient than H-DFO. AZM rapidly accumulates inside
the cells and lysosomes through a concentration- and pH-
dependent passive diffusion [24-26], while the fluid-phase
endocytosis of H-DFO is far less effective and a slower
process for a lysosomal deposition of drugs. Thus, AZM is
lysosomotropic, which has been demonstrated in previous
studies on a number of cell types including J774macrophages [24-26]. In line with these previous findings
we demonstrated an almost complete loss of cell protec-
tion by AZM in the presence of a brief exposure to NH4Cl
that raised the pH of the lysosomes (Figure 4).
Overall, our findings are consistent with previous re-
search demonstrating a disturbed Fe metabolism in lung
transplants [49-51]. However, the present study expands
our understanding greatly about how oxidative damage
in the lung transplant may be mediated, pointing out the
important role of lysosomes. The observations of the
present study also indicate that AZM effectively prevents
oxidative damage on lysosomes and concomitant cell
death. It seems that AZM exerts an immediate effect on
a currently unknown lysosomal product that is harmful
during an oxidant challenge. We believe that the most
likely candidate would be free or loosely bound lyso-
somal Fe that is in a reactive state, but further studies
are warranted.
Conclusions
The present study is the first to show that lung macro-
phages derived from human lung transplant recipients,
as compared to lung macrophages of healthy subjects,
are sensitized to oxidative stress in cultures and have
lysosomes that are more prone to leakage due to a dis-
turbed balance of Fe. Moreover, lung macrophages (and
their lysosomes) become significantly less susceptible to
oxidant challenge in vitro, when treated with the lysoso-
motropic antibiotic AZM in vivo. Collectively, experi-
ments on transplant lung macrophages and murine J774
macrophages suggest that protection against oxidants
afforded by AZM is mediated by this drug attenuating
the reactivity of the lysosomal pool of Fe. Given that
oxidant-induced LMP and lung macrophage death is of
some importance for BOS development in lung trans-
plants, we propose that the preventive effect of AZM
against BOS is at least partly due to its protective effects
on lysosomes and cells.
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